2014, Number S1
<< Back Next >>
Rev Med Inst Mex Seguro Soc 2014; 52 (S1)
Nonalcoholic fatty liver disease in children
Bojórquez-Ramos MC
Language: Spanish
References: 25
Page: 110-114
PDF size: 181.96 Kb.
ABSTRACT
Nonalcoholic fatty liver disease (NAFLD) is currently the most common
cause of liver disease in children and adolescents in the United States
of America (USA) and probably in the entire western hemisphere, due to
the increase in the prevalence of overweight and obesity. Steatosis can
progress to infl ammation, fibrosis and even cirrhosis, which increases
the morbidity and mortality associated to liver disease. In every overweight
and obese child a thorough analysis should be performed including
liver function tests and liver ultrasound, in order to establish a timely
diagnosis. The liver biopsy is the most specifi c study to rule out other
potentially treatable entities. It is necessary to count on non-invasive
methods to detect children with NAFLD and identify those in risk of progression.
Biomarkers related to inflammation, oxidative stress, apoptosis
and fibrosis have been reported. The main goal of the treatment is to
modify the life style, starting with a healthy diet and an increase of physical
activity. Regarding pharmacological treatment, there is evidence of
histological improvement with vitamin E use, as opposed to metformin,
but more conclusive studies regarding this subject are needed.
REFERENCES
Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Ga stroenterology. 2012;142(7):1592-609.
Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C. Prevalence of fatty liver in children and adolescents. Pediatrics. 2006;118:1388-93.
Flores J, Gómez R, Rodríguez G, Morán S. Prevalence of Nonalcoholic Steatohepatitis (NASH) in Mexican Children of An Elementary School. J Pediatr Gastroenterol Nutr. 2004;39:S143.
Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, Baumann U, et al: Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee. J Pediatr Gastroenterol Nutr. 2012;54(5):700-13.
Schwimmer JB, McGreal N, Deutsch R, Finegold MJ, Lavine JE. Infl uence of gender, race, and ethnicity on suspected fatty liver in obese adolescents. Pediatrics. 2005;115(5):e561-e5.
Nobili V, Alisi A, Panera N, Agostoni C. Low birth weight and catch-up-growth associated with metabolic syndrome: a ten year systematic review. Pediatr Endocrinol Rev. 2008;6:241-7.
Nobili V, Bedogni G, Alisi A, Pietrobattista A, Alterio A, Tiribelli C, et al. A protective effect of breastfeeding on the progression of NAFLD. Arch Dis Child. 2009;94(10):801-5.
Abdelmalek MF, Suzuki A, Guy C, Unalp-Arida A, Colvin R, Johnson RJ, et al. Increased fructose consumption is associated with fi brosis severity in patients with nonalcoholic fatty liver disease. Hepatology. 2010;51:1961-71.
Day CP. Genetic and environmental susceptibility to nonalcoholic fatty liver disease. Dig Dis. 2010;28(1):255-60.
Sundaram SS, Zeitler P, Nadeau K. The metabolic syndrome and nonalcoholic fatty liver disease in children. Curr Opin Pediatr. 2009;21:529-35.
Schwimmer JB, Pardee PE, Lavine JE, Blumkin AK, Cook S. Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease. Circulation. 2008;118:277-83.
Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003;143:500-5.
Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, et al: Histopathology of pediatric nonalcoholic fatty liver disease. Hepatology. 2005;42(3):641-9.
Lin YC, Chang PF, Yeh SJ, Liu K, Chen HC. Risk factors for liver steatosis in obese children and adolescents. Pediatr Neonatol. 2010;51(3):149-54.
Tahan V, Canbakan B, Balci H, Dane F, Akin H, Can G, et al. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology. 2008;55:1433-8.
Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in Pediatric Nonalcoholic Fatty Liver Disease. Hepatology. 2009;50(4):1282-93.
Joseph AE, Saverymuttu SH, al-Sam S, Cook MG, Maxwell JD. Comparison of liver histology with ultrasonography in assessing diffuse parenchymal liver disease. Clin Radiol. 1991;43(1):26-31.
Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol. 2009;51:1061-7.
Park SH, Kim PN, Kim KW, Lee SW, Yoon SE, Park SW, et al. Macrovesicular hepatic steatosis in living liver donors: use of CT for quantitative and qualitative assessment. Radiology. 2006;239(1):105-12.
Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21.
Patton HM, Sirlin C, Behling C, Middleton M, Schwimmer JB, Lavine JE. Pediatric Nonalcoholic Fatty Liver Disease: A Clinical Appraisal of Current Data and Implications for Future Research. J Pediatr Gastroenterol Nutr. 2006;43:413-27. doi: 10.1097/01. mpg.0000239995.58388.56.
Ebbeling CB, Leidig MM, Feldman HA, Lovesky MM, Ludwig DS. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial. JAMA 2007;297(19):2092-102.
De Piano A, Prado WL, Caranti DA, Siqueira KO, Stella SG, Lofrano M, et al. Metabolic and Nutritional Profi le of Obese Adolescents With Nonalcoholic Fatty Liver Disease. J Pediatr Gastroenterol Nutr. 2007;44(4):446-52.
Alisi A, Nobili V: Non-alcoholic fatty liver disease in children now: lifestyle change and pharmacologic treatments. Nutrition. 2012; 28(7-8):722-6.
Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, et al: Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659- 68. doi: 10.1001/jama.2011.520.